NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









D3 Bio

D3 Bio

Private
ShanghaiHealthcare & Life Scienceshttps://www.d3bio.com/

Last Round

Series B

Dec 9, 2025

Total Funding Raised

$370M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

D3 Bio is a biotechnology company that develops and registers innovative medicines in the fields of oncology and immunology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision oncologyKRAS inhibitorbiotechoncology therapeuticsclinical-stage biotechKRAS G12Cdrug discoveryclinical trialsinvestigational new drugINDsolid tumorsnon-small cell lung cancerNSCLCsmall molecule drugspharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

D3 Bio Comparables

Compare D3 Bio with similar companies based on industry and business-model similarity.

D3 Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Frontier Medicines
87%
GenFleet Therapeutics
86%
Shanghai Jeyou Pharmaceutical Technology Co., Ltd.
85%

D3 Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 9, 2025
Series A ExtensionApr 8, 2024
Series ANov 17, 2020

Key People

Founding team and executive leadership

John J.

Co-Founder CFO CBO

Founding Team

D3 Bio Investors

Notable investors and investment history

D3 Bio investors
InvestorRounds
MatrixSeries A, Series A Extension
IDG CapitalSeries B
Boyu CapitalSeries A
TemasekSeries B, Series A
MPCSeries B, Series A Extension, Series A
HongShan Capital Group (HSG)Series B, Series A
MedicxiSeries B, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 207% MoM.

  • Apr 17, 2026

    Monthly visitors increased 45% MoM, from 1.4K to 2K.

D3 Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

D3 Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about D3 Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range25
Year Founded2020
Last FundingDec 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.